Go Pro
NASDAQ:IMA

ImageneBio Q1 2026 Earnings Report

ImageneBio logo
$4.87 +0.02 (+0.37%)
Closing price 09/23/2026 03:58 PM Eastern
Extended Trading
$4.86 -0.01 (-0.27%)
As of 09/23/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImageneBio EPS Results

Actual EPS
-$0.95
Consensus EPS
-$0.70
Beat/Miss
Missed by -$0.25
One Year Ago EPS
N/A

ImageneBio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImageneBio Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Thursday, May 7, 2026
Conference Call Time
8:00AM ET

ImageneBio Earnings Headlines

ImageneBio, Inc. (NASDAQ:IMA) Receives $29.00 Average PT from Analysts
ImageneBio Corporate Event Calendar | NASDAQ:IMA
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.tc pixel
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
See More ImageneBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email.

About ImageneBio

ImageneBio (NASDAQ:IMA) is a biotechnology company focused on precision oncology and the development of blood-based tools for cancer research and clinical care. The company’s work centers on analyzing tumor-derived genetic material found in blood, with the goal of providing noninvasive information about a patient’s cancer.

Its technology is designed to support tumor profiling, biomarker identification, and the monitoring of disease over time. By combining molecular analysis with computational methods, ImageneBio aims to help physicians and researchers characterize tumors, identify potentially relevant treatment options, and evaluate changes in tumor biology.

Publicly available information about ImageneBio’s commercial portfolio, geographic operations, and leadership is limited. The company is associated with the ticker symbol IMA on the Nasdaq Stock Market.

View ImageneBio Profile